Trial · NCT01824264
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
NCT01824264, Phase 2, Withdrawn, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes. Trials, record NCT01824264. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01824264
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
- NCT number
- NCT01824264
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LIK066, Sitagliptin, Placebo
- First posted
- 2013-04-04
- Last updated
- 2014-04-03
- Other registries' IDs
- eudract:2012-005793-63
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks | baseline, 12 weeks | Change from baseline in HbA1c after 12 weeks of treatment in each of the LIK066 doses and placebo |
| Secondary | Change from baseline in Fasting Plasma Glucose | baseline, 12 weeks | The effect of LIK066 on fasting plasma glucose after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in urinary glucose to creatinine ratio | baseline, 12 weeks | The effect of LIK066 on urinary glucose to creatinine ratio after 12 weeks of treatment will be evaluated |
| Secondary | Change from baseline in Body weight | baseline, 12 weeks | The effect of LIK066 on change in body weight after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in Blood pressure | baseline, 12 weeks | The effect of LIK066 on change in systolic and diastolic blood pressure after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in postprandial glucose during a meal test | baseline, 12 weeks | The effect of LIK066 on change in postprandial glucose during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in beta cell function during a meal test | baseline, 12 weeks | The effect of LIK066 on change in beta cell function during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in insulin secretion relative to glucose during a meal test | baseline, 12 weeks | The effect of LIK066on change in insulin secretion relative to glucose during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in oral glucose insulin sensitivity during a meal test | baseline, 12 weeks | The effect of LIK066 on change in oral glucose insulin sensitivity during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in glucagon-like peptide response during a meal test | baseline, 12 weeks | The effect of LIK066 on change in glucagon-like peptide during a meal test after 12 weeks of treatment will be evaluated. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01824264
GET https://conductscience.org/api/trials/v1/NCT01824264/registered